Every 10-Q that VIREO GROWTH INC (VREOF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VREOF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VREOF filings page.
Vireo Growth Inc. reported sharp expansion for the six months ended June 30, 2026, driven by multiple acquisitions and a new non-cannabis segment. Revenue rose to $315.5 million from $72.6 million a year earlier, with second‑quarter revenue of $209.3 million. Despite this growth, the company recorded a six‑month net loss of $20.4 million, though second‑quarter results were close to breakeven.
Total assets increased to $1,273.7 million, including cash of $103.1 million and restricted cash of $19.6 million, while total liabilities were $831.2 million. Long‑term debt (excluding current portion) rose to $257.2 million and convertible debt to $22.3 million. Operating activities generated $14.3 million of cash, offset by $61.7 million used in investing and $47.6 million provided by financing.
The company completed the acquisitions of Eaze, Hawthorne, Bridgewell, and Vireo Health of Rocky Mountain, significantly enlarging its retail cannabis footprint and adding a non‑cannabis horticulture and agricultural products segment. The Hawthorne deal generated a $21.7 million bargain purchase gain. Vireo also effected a 30‑for‑1 share consolidation, leaving 45,044,826 Subordinate Voting Shares outstanding at June 30, 2026. A recent DEA rule rescheduling qualifying medical marijuana to Schedule III is expected to allow state‑licensed medical operators to deduct ordinary business expenses for U.S. federal tax purposes.
Vireo Growth Inc. reported much larger operations for the quarter ended March 31, 2026, driven by multiple acquisitions and a major asset purchase. Revenue rose to $106.2M from $24.5M a year earlier, with retail sales of $89.9M and wholesale of $16.3M.
Despite a higher gross profit of $59.3M, the company posted a net loss of $20.3M, compared with a $6.5M loss in 2025, mainly due to higher operating costs, transaction expenses, stock-based pay, and income taxes. Total assets increased to $928.8M, total liabilities to $634.7M, and cash plus restricted cash to $137.8M. Vireo completed or integrated several cannabis deals (Wholesome, Proper, Deep Roots, Vireo Health of Rocky Mountain/Schwazze) and added goodwill and licenses, while assuming new long-term and high‑coupon debt and lease obligations.
Vireo Growth Inc. reported sharply larger operations following three acquisitions completed in 2025. Q3 revenue rose to $91.7 million from $25.2 million a year ago, driven by retail sales of $76.0 million and wholesale of $15.7 million. For the first nine months, revenue reached $164.3 million versus $74.4 million last year.
Despite higher sales, the company posted a Q3 net loss of $26.3 million and a nine‑month net loss of $47.7 million. Results included $12.4 million of non‑cash product cost from inventory step‑up and a $8.6 million loss on debt extinguishment tied to refinancing. Operating expenses also increased with integration, stock‑based compensation, and amortization.
Vireo closed the Wholesome, Proper, and Deep Roots deals using all‑share consideration, lifting intangible assets and goodwill to $97.3 million. To refinance and fund the combined platform, the company entered a $120 million First Lien Term Loan and a $33 million Chicago Atlantic Term Loan, and added interest rate swaps. Cash was $97.2 million plus $20.4 million of restricted cash at quarter‑end. Total assets were $678.9 million, with long‑term debt of $131.7 million and convertible debt of $8.2 million. Certain New York, Nevada, and Massachusetts assets were classified as held for sale.